Sign in
Taking people in South KoreaPhase 3

Tests inclisiran started early after hospital admission for serious heart conditions

Compares inclisiran with placebo, alongside standard care, in adults with acute coronary syndromes.

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Seoul, South KoreaSee the siteAlso in 13 other countries, 59 sites
Registry title
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Status
Recruiting
Phase
Phase 3
People taking part
300 people, planned
Started
3 Oct 2025
Expected to end
11 Feb 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Placebo
  • Inclisiran
Record updated
16 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults in hospital with a heart attack (STEMI or NSTEMI) who still have high LDL cholesterol. It tests inclisiran against placebo, started early in hospital.

Age
18 years or older
Sex
Men and women
Disease stage
Hospitalised for an acute coronary syndrome (STEMI or NSTEMI). Treated with medicines alone or with a successful PCI. Randomised within 7 days of admission and before or at discharge.
Earlier treatment
LDL-C cut-offs depend on prior statin use: 70 mg/dL (1.8 mmol/L) or more after at least 4 weeks of high-intensity statin, 80 mg/dL or more on low or moderate-intensity statin, 100 mg/dL or more with no statin.
Biomarker or test result
LDL cholesterol (LDL-C) of 70 mg/dL (1.8 mmol/L) or more at baseline, fasting, measured by the local lab.

Main reasons for not taking part

  • Unstable condition in the 24 hours before randomisation, such as shock, NYHA class IV heart failure or severe uncontrolled high blood pressure
  • Bypass surgery (CABG) done or planned for the heart attack
  • Active liver disease or kidney function eGFR below 30 mL/min/1.73m2
  • Homozygous familial hypercholesterolemia, secondary hypercholesterolemia or apheresis
  • Current or past muscle disease (myopathy) or high CK of 5x ULN or more

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Participant eligible for inclusion in this study must meet all the following criteria:
  • At Screening:
  • Signed informed consent must be obtained prior to participation in the study
  • Males and females, ≥18 years of age at the time of providing written informed consent
  • Ability to understand study's requirements and provide informed consent and comply with all required study procedures
  • Hospitalization for a ACS event (STEMI or NSTEMI)
  • Receiving treatment for the qualifying ACS event, according to clinical judgement, by means of medical treatment alone or percutaneous coronary revascularization
  • Had a successful PCI (with or without stent) for the qualifying event if a PCI was required
  • LDL-C values measured by the local lab either at the Screening visit or results from local lab tests performed prior to ICF signature, strictly as part of the routine clinical practice in this emergency ACS setting and not older than 2 days of:; LDL-C ≥70 mg/dL in participant previously treated with high-intensity statin (atorvastatin ≥40 mg/day or rosuvastatin ≥20 mg/day) or equivalent as per national guidelines and local regulation for at least 4 weeks before screening or; LDL-C ≥80 mg/dL in participant previously treated with low/moderate-intensity statin for at least 4 weeks before screening or; LDL-C ≥100 mg/dL in participant previously not treated with statins for at least 4 weeks before screening, or who never received statins (including statin intolerant participants); At Randomization:
  • The participant must have a Baseline fasting LDL-C ≥70 mg/dL (local lab assessment) to be eligible for randomization
  • Randomization within 7 days (≤ 7 days) following hospital admission for the qualifying ACS event and before/at discharge

Who cannot take part

  • Ongoing or medical history of myopathy at the Screening visit
  • Participant who is clinically unstable during hospitalization for the qualifying ACS event, defined by any of the following events within 24 hours prior to randomization:; Hemodynamic instability: hypotension, defined as sustained systolic blood pressure of <90 mmHg due to cardiac failure with associated symptoms requiring inotropes; Sustained arrhythmic events such as: ventricular storm (e.g., torsade, ventricular tachycardia, ventricular flutter) not resolved before randomization; Cardiogenic shock or mechanical complication of myocardial infarction; New York Heart Association (NYHA) class IV heart failure; Left ventricular ejection fraction <20% at randomization (after all treatment procedures, based on the latest assessment of the LVEF using invasive or non-invasive assessment modalities); Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization despite antihypertensive therapy
  • Active liver disease defined as: (i) any known current infectious, neoplastic, or metabolic pathology of the liver or (ii) alanine aminotransferase (ALT) elevation >3x ULN or aspartate aminotransferase (AST) elevation >3x ULN, or total bilirubin elevation >2x ULN (except participant with Gilbert's syndrome) at the Screening visit, in the context of an ACS, and assessed as related to the index event and/or treatment procedures (such as PCI). Eligibility will be based on Investigator's judgement for participant who will be randomized
  • Renal insufficiency (eGFR <30 mL/min/1.73m2) at the Screening visit
  • Fasting triglycerides value >400 mg/dL (4.52 mmol/L; assessed by local labs) at randomization visit
  • Participant, who based on the Investigator's judgement, could reach the LDL-C target value of <55 mg/dL after 4 weeks on statin treatment only
  • CK values ≥5x ULN at Screening visit and confirmed by repeat test during Screening (local lab) , in the context of an ACS, and assessed as related to the index event and/or treatment procedures (such as PCI) eligibility will be based on Investigator's judgement for participant who will be randomized (who will be switched to or initiated on the protocol-specified dose of high-intensity statin of atorvastatin ≥40 mg QD or rosuvastatin ≥20 mg QD). Unless a more stringent CK value threshold is mandated by a local regulatory authority (e.g., ≥3x ULN in Korea according to MFDS internal guideline)
  • Participant meeting any of the following criteria is not eligible for inclusion in this study
  • Only for Japan: For exclusion criteria 6, investigator judgment should be documented in the source data document
  • Participant who has undergone or is scheduled to undergo CABG for treatment of the qualifying ACS event
  • Secondary hypercholesterolemia (based on medical history)
  • Homozygous familial hypercholesterolemia (based on medical history)
  • Participant on apheresis at the Screening visit or for whom an apheresis is planned during study (from Day 1 to EOS)

Where in South Korea

Also in 13 other countries, 59 sites

  • Seoul, KoreaHospital not named in the registryContact: Novartis PharmaceuticalsTaking people

About the trial

What the trial wants to find out

The purpose of this trial is to learn about the effects of inclisiran in people with serious heart conditions (acute coronary syndromes), when this treatment is started early after hospital admission. To do this, researchers will test the effects of inclisiran compared to placebo, when given with standard treatment.

The 2 groups in the trial

  • Inclisiran sodium 300 mg s.c. + Standard treatmentTreatment being tested

    * Inclisiran sodium 300 mg subcutaneous (s.c.) on top of HIS (+/- LLT) or non-statin LLT in statin intolerant participants * KJX839 284 mg / 1.5 mL (Dose: 300 mg) * Pharmaceutical Dosage Form: solution for subcutaneous injection

    Treatment: Inclisiran

  • Matching placebo + Standard treatmentPlacebo, for comparison

    * Matching placebo on top of HIS (+/- LLT) or non-statin LLT in statin intolerant participants * KJX839 Placebo / 1.5 mL (Dose: 0 mg) * Pharmaceutical Dosage Form: solution for subcutaneous injection

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes: Victorion - RIDES
Plain-language title
Tests inclisiran started early after hospital admission for serious heart conditionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
16 September 2026